Ipsilateral lung dose as a correlative measure for radiation pneumonitis in patients treated with definitive concurrent radiochemotherapy

被引:1
|
作者
Kirakli, Esra Korkmaz [1 ]
Erdem, Sevilay [1 ]
Susam, Seher [2 ]
Erim, Eser [1 ]
机构
[1] Dr Suat Seren Chest Dis & Surg Res & Training Hos, Dept Radiat, Izmir, Turkiye
[2] Dr Suat Seren Chest Dis & Surg Res & Training Hos, Dept Radiol, Izmir, Turkiye
关键词
Ipsilateral lung dose; nonsmall cell lung cancer; radiation pneumonitis; radiochemotherapy; VOLUME HISTOGRAM PARAMETERS; REGIONAL DIFFERENCES; CANCER PATIENTS; PHASE-II; RADIOTHERAPY; TOXICITY; THERAPY; CHEMORADIATION; PREDICTION; CRITERIA;
D O I
10.4103/jcrt.jcrt_618_21
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: Mean lung dose (MLD) and percent of total lung (TL) volume that receive a dose greater than 20 Gy (V-20) have been the most validated parameters in the prediction of radiation pneumonitis (RP). However, these parameters present mean values of TL parenchyma and predict the right and the left lung as a unique functional organ unit, not take into account the difference in function and dose density between the lungs. Furthermore, there have been very limited data evaluating ipsilateral lung dosimetric constraints in addition to TL parameters to predict RP in non-small cell lung cancer (NSCLC) patients treated with radiochemotherapy (RCT). Methods: Between 2010 and 2017, clinical-radiological findings of NSCLC patients treated with RCT were evaluated in terms of RP, retrospectively. MLD, V-20, and V-30 values of ipsilateral lung were assessed from dose-volume histogram and registered. The primary endpoint was to assess the relation between ipsilateral lung dose constraints and RP risk. Results: There were 75 patients. There was >= Grade 2 RP in 33 cases (%44). In univariate analysis, ipsilateral MLD, ipsilateral V-20, ipsilateral V-30,V- and TL V-30 were found to be significant. Ipsilateral MLD and PTV were found to be the independent risk factors for RP. Cutoff values for RP risk were determined as 18Gy, 35%, and 28% for ipsilateral MLD, ipsilateral V-20, and ipsilateral V-30, respectively. Predictive values for ipsilateral MLD and ipsilateral V-20 were higher than TL. Conclusions: In NSCLC patients treated with RCT, MLD, V-20, and V-30 values of ipsilateral lung parameters might increase the predictability of RP risk in addition to TL parameters. Advances in Knowledge: Cutoff values for RP risk were determined as 18Gy, 35%, and 28% for ipsilateral MLD, ipsilateral V-20, and ipsilateral V-30, respectively. Predictive values for ipsilateral MLD and ipsilateral V-20 were higher than TL.
引用
收藏
页码:2023 / 1159
页数:7
相关论文
共 50 条
  • [1] Radiation pneumonitis in lung cancer patients treated with high dose radiotherapy - Role of concurrent medications
    Bezjak, A
    Soyfer, V
    Yi, QL
    Sun, A
    Kane, G
    Waldron, J
    Cho, J
    Wells, W
    Payne, D
    RADIOTHERAPY AND ONCOLOGY, 2005, 76 : S21 - S22
  • [2] Ipsilateral Lung Dose Constraints Predict Radiation Pneumonitis Better Than Conventional Ones in NSCLC Patients Treated with RCT
    Kirakli, E. Korkmaz
    Erdem, S.
    Erim, E.
    Yalman, D.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S657 - S657
  • [3] THE RELATION BETWEEN RADIATION PNEUMONITIS AND MEAN LUNG DOSE IN PATIENTS TREATED WITH LUNG SBRT
    Scheenstra, Alize
    Rossi, Maddalena M. G.
    Damen, Eugene
    Belderbos, Jose
    Peulen, Heike
    Sonke, Jan Jakob
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S541 - S542
  • [4] SGA Could Be a Predictive Factor for Radiation Pneumonitis in Lung Cancer Patients Treated by Concurrent Chemoradiotherapy
    Ma, L.
    Ye, W.
    Li, Q.
    Wang, B.
    Luo, G.
    Chen, Z.
    Guo, S.
    Qiu, B.
    Liu, H.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2039 - S2039
  • [5] Spatial dose patterns of radiation pneumonitis in lung cancer patients treated by photons or protons
    Palma, G.
    Monti, S.
    Xu, T.
    Scifoni, E.
    Yang, P.
    Hahn, S.
    Durante, M.
    Mohan, R.
    Liao, Z.
    Cella, L.
    RADIOTHERAPY AND ONCOLOGY, 2019, 133 : S324 - S325
  • [6] Temporal and spatial dose distribution of radiation pneumonitis after concurrent radiochemotherapy in stage III non-small cell cancer patients
    Alharbi, Mohammed
    Janssen, Stefan
    Golpon, Heiko
    Bremer, Michael
    Henkenberens, Christoph
    RADIATION ONCOLOGY, 2017, 12
  • [7] Temporal and spatial dose distribution of radiation pneumonitis after concurrent radiochemotherapy in stage III non-small cell cancer patients
    Mohammed Alharbi
    Stefan Janssen
    Heiko Golpon
    Michael Bremer
    Christoph Henkenberens
    Radiation Oncology, 12
  • [8] Impact of Dose-Volume Parameters and Tumor Location on Severe Acute Radiation Pneumonitis for Lung Cancer Patients Treated With Concurrent Chemoradiation Therapy
    Wang, J.
    Bao, Y.
    Zhuang, T.
    He, Z.
    Zhang, L.
    Tai, A.
    Prior, P.
    Chen, M.
    Li, X.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 84 (03): : S756 - S757
  • [9] Concurrent medications as potential modifiers of radiation pneumonitis in lung cancer patients
    Bezjak, A
    Soyfer, V
    Yi, Q
    Sun, A
    Kane, G
    Waldron, J
    Cho, J
    Wells, W
    Payne, D
    LUNG CANCER, 2005, 49 : S331 - S332
  • [10] PREDICTIVE FACTORS FOR RADIATION PNEUMONITIS BASED ON DOSE VOLUME HISTOGRAM ANALYSIS OF PATIENTS WITH ESOPHAGEAL CANCER TREATED WITH DEFINITIVE RADIOTHERAPY
    Nomura, M.
    Kodaira, T.
    Furutani, K.
    Tachibana, H.
    Tomita, N.
    Goto, Y.
    RADIOTHERAPY AND ONCOLOGY, 2010, 96 : S287 - S288